Do SLC30A8 rs13266634 and MTNR1B rs10830963 variants increase glucose-handling vulnerability?

Genetic variations in pancreatic beta-cell function are primary drivers of metabolic susceptibility, with specific polymorphisms directly influencing basal glycemia and insulin kinetics.

Mechanistic pathways

• SLC30A8 rs13266634: The risk C (Arg325) allele alters ZnT8 zinc transport capacity into insulin granules. This transport shift promotes toxic amyloid aggregation and calcium channel inhibition, which compromises insulin crystallization and blunts early-phase insulin release.
• MTNR1B rs10830963: The G risk allele drives MTNR1B receptor overexpression in pancreatic islets. This enhances melatonin-mediated Gi/o signaling, which inhibits adenylyl cyclase and reduces intracellular cAMP, directly limiting the amplification of glucose-stimulated insulin exocytosis.

Clinical evidence and glucose regulation

• Secretory defects: Both variants systematically impair first-phase insulin secretion. In clinical cohorts, carriers exhibit decreased acute insulin responses and lower beta-cell secretory indices under glucose challenges.
• Fasting glucose elevation: Meta-analyses and genome-wide association studies (GWAS) show that each risk allele incrementally elevates fasting plasma glucose levels and lowers HOMA-B indices, reflecting a primary defect in basal pancreatic function rather than peripheral insulin resistance.
• Glucose-handling vulnerability: The convergence of blunted insulin release and elevated fasting glycemia impairs dynamic glucose clearance. This metabolic state directly increases clinical susceptibility to impaired glucose tolerance and type 2 diabetes.

Bottom line

• The SLC30A8 rs13266634 and MTNR1B rs10830963 variants are strongly associated with glucose-handling vulnerability, operating through distinct molecular pathways that impair beta-cell insulin secretion dynamics and elevate fasting plasma glucose.